Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#4085 Disease-specific mortality in a single-center cohort of 427 patients with carcinoid syndrome

Introduction: The carcinoid syndrome (CS), the most prevalent hormonal syndrome in patients with a neuroendocrine tumor (NET), is associated with impaired survival. Due to the biological behaviour of NET and overall improvement in survival rates, patients with CS may not succumb to their disease. However, the contribution of NET-specific death in these patients is currently unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Feelders R, de Herder W, Hofland J,

Keywords: carcinoid syndrome, neuroendocrine tumor, prognosis, survival analysis,

#4021 What is the carcinoid syndrome? A critical appraisal of its proposed mediators

Introduction: Carcinoid syndrome (CS) is a debilitating disease that affects approximately 20% of patients with neuroendocrine neoplasms (NEN). Due to the increasing incidence and improved overall survival of patients with NEN over recent decades, patients are increasingly suffering from chronic and refractory CS symptoms. At present, symptom control is hampered by an incomplete understanding of the pathophysiology of this syndrome.

Conference:

Presenting Author: Mulders M

Authors: Mulders M, de Herder W, Hofland J,

Keywords: carcinoid, syndrome, neuroendocrine, tumor, serotonin, tachykinin, catecholamine, histamine,

#4020 Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients

Introduction: Neuroendocrine tumors (NET) are malignant neoplasms that can be associated with specific hormonal syndromes.

Conference:

Presenting Author: Mulders M

Authors: Mulders M, Hofland J, de Herder W, van Velthuysen M, Roes E,

Keywords: ovary, neuroendocrine, tumor, estradiol, postmenopausal, bleeding,

#4017 Serum 5-hydroxyindoleacetic acid is equivalent to 24-hour urinary 5-hydroxyindoleacetic acid for the diagnosis of carcinoid syndrome

Introduction: Neuroendocrine tumors (NET) are characterized by their ability to secrete amines and peptides. Overproduction of serotonin results in the carcinoid syndrome (CS), present in approximately 20% of all NET patients. Measuring the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in 24-hour urine is frequently used for the diagnosis and follow-up of CS patients. However, these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might be a more reliable and convenient alternative in the diagnosis of CS.

Conference:

Presenting Author:

Authors: Kerolles M, Mulders M, Mirzaian M, van den Berg S, Feelders R,

Keywords: 5-hiaa, carcinoid syndrome, neuroendocrine tumor, biomarker,